Company
Accord
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
8
8 still marketed
Novel approvals
0
Approvals since 2021
8
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Immgolis approved May 15, 2026
- Ennumo approved May 7, 2026
- Filkri approved Jan 15, 2026
- Osvyrti approved Oct 29, 2025
- Camcevi Etm approved Aug 25, 2025
- Imuldosa approved Oct 10, 2024
- Hercessi approved Apr 25, 2024
- Camcevi Kit approved May 25, 2021
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (8)
Newest FDA action first.
- Camcevi Etm Leuprolide Mesylate · 2025
- Imuldosa Ustekinumab-Srlf · 2024
- Immgolis Golimumab-Sldi · 2026
- Ennumo Pegfilgrastim-Pccg · 2026
- Camcevi Kit Leuprolide Mesylate · 2021
- Filkri Filgrastim-Laha · 2026
- Osvyrti Denosumab-Desu · 2025
- Hercessi Trastuzumab-Strf · 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.